4 November 2020Cigarette smoking leads to both oral and inhalational exposure of breastfed infants to cigarette constituents, including nicotine, although no adverse effects due to ingestion of…
23 March 2020This Medicines Q&A summarises those drug interactions with tobacco smoking that are considered to be most clinically important. Most interactions between drugs and tobacco smoking…
Lactation Safety Information
Lower levels of nicotine anticipated in milk from NRT products than from cigarette smoking
Limited evidence of safety of nicotine in breast milk following use of NRT products
Lower strength transdermal nicotine patches preferred
23 September 2020
VokeSmoking cessation; nicotine inhaler formulation
Development and Regulatory status
Dec 19The licensed indication is Voke relieves and/or prevents craving and nicotine withdrawal symptoms associated with tobacco dependence. It is indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them. Voke is indicated in pregnant and lactating women making a quit attempt .
Nov 19Launched in UK. 450 microgram per charge, stick inhaler plus canister containing 20 charges, 1 pack=£8.00; 2 packs=£15.84; 5 packs=£38.80 .
May 19Company website still states launch planned for 2019 .
May 18Kind Consumer hope to launch in the first half of 2019 .
May 17Kind Consumer is reassembling the manufacturing supply chain which requires a variation to the Marketing Authorisation from the MHRA. They hope to launch in 2018 .
May 17Voke 0.45mg Inhaler will be available on General Sale List in the UK .
Jan 17Kind will seek a new global partner, or possibly several regional partners, to accelerate distribution of the inhaler this year .
Jan 17British American Tobacco (BAT) quits plans to market Voke to focus on consumer items like e-cigarettes rather than health products. They have decided to move away from the very diversified approach to cigarette alternatives, which are being pursued by all big listed tobacco companies including Philip Morris International and Japan Tobacco International as a growing health consciousness reduces smoking rates. The decision of BAT to narrow its focus comes after manufacturing issues delayed the launch of Voke, which was the first product approved by Britain´s drug regulator to be prescribed as a medical aid to quit smoking. It will now be marketed by BAT partner Kind Consumer .
Jan 16Voke is licensed to be used whenever the urge to smoke is felt or to prevent cravings in situations where these are likely to occur. Maximum daily dose of 2 packs, each pack contains 9mg of nicotine .
Jan 16A variation to the Voke licence to support full commercialisation has been granted. Nicovations is working towards launch but cannot give any indication on timing at this point .
Sep 14Nicovations , a wholly owned subsidiary of British American Tobacco plc (BAT), announced that Kind Consumer, its development partner since 2011, was granted the licence. Kind Consumer will pursue a variation to the licence for a further evolution of the technology to support full-scale commercialisation by Nicovations .
Sep 14Approved by the MHRA .
Voke is a cigarette shape nicotine inhaler that doesn’t heat liquid, use a battery or create vapour. Voke relieves and/or prevents craving and nicotine withdrawal symptoms associated with tobacco dependence.
Nearly one in five adults (19%) aged 16 and over were smokers in 2013, a rate that although slightly less than 2012, has remained largely unchanged in recent years .
Smoking cessation; nicotine inhaler formulation
Trial or other data
Sep 18Commissioned by CCGs, NHS England & local authorities .
Feb 16Voke has been designed for smokers who want to reduce, replace or stop smoking. Voke involves no heat or combustion, and so produces no ash or smoke. It also requires no battery or other energy source, it is activated simply by the user inhaling .